BridgeBio Pharma, Inc. (BBIO) Earnings History
Annual and quarterly earnings data from 2017 to 2025
Loading earnings history...
BBIO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BBIO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 94.4% | -113.3% | -145.3% |
| 2024 | 98.3% | -267.2% | -241.4% |
| 2023 | 73.7% | -6528.8% | -6913.9% |
| 2022 | 95.6% | -659.6% | -619.7% |
| 2021 | 95.5% | -827.1% | -806.9% |
Download Data
Export BBIO earnings history in CSV or JSON format
Free sign-in required to download data
BridgeBio Pharma, Inc. (BBIO) Earnings Overview
As of May 8, 2026, BridgeBio Pharma, Inc. (BBIO) reported trailing twelve-month net income of -$726M, reflecting -31.6% year-over-year growth. The company earned $-3.73 per diluted share over the past four quarters, with a net profit margin of -145.3%.
Looking at the long-term picture, BBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$31M in fiscal 2017.
BridgeBio Pharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KYMR (-$315M net income, -794.4% margin), ARRY (-$67M net income, -4.1% margin), RCUS (-$369M net income, -142.9% margin), BBIO has outperformed on profitability metrics. Compare BBIO vs KYMR →
BBIO Earnings vs Peers
Earnings metrics vs comparable public companies
BBIO Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$729M | -36.1% | -$569M | $-3.79 | -145.3% | -113.3% |
| 2024 | -$536M | +16.7% | -$593M | $-2.88 | -241.4% | -267.2% |
| 2023 | -$643M | -33.7% | -$607M | $-3.95 | -6913.9% | -6528.8% |
| 2022 | -$481M | +14.5% | -$512M | $-3.35 | -619.7% | -659.6% |
| 2021 | -$563M | -25.4% | -$577M | $-3.90 | -806.9% | -827.1% |
| 2020 | -$449M | -72.3% | -$474M | $-4.10 | -5439.7% | -5752.0% |
| 2019 | -$260M | -99.2% | -$266M | $-2.48 | -642.1% | -656.4% |
| 2018 | -$131M | -327.8% | -$184M | $-1.42 | - | - |
| 2017 | -$31M | - | -$44M | $-0.33 | - | - |
Full BBIO Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See BBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BBIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBBIO — Frequently Asked Questions
Quick answers to the most common questions about buying BBIO stock.
Is BBIO growing earnings?
BBIO EPS fell to $-3.73, with earnings declining -31.6%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-726M.
What are BBIO's profit margins?
BridgeBio Pharma, Inc. net margin is -145.3%, with operating margin at -113.3%. Below-average margins reflect competitive or cost pressures.
How consistent are BBIO's earnings?
BBIO earnings data spans 2017-2025. The declining earnings trend is -31.6% YoY. Historical data enables comparison across business cycles.